Skip to content
Research Article Open access CC BY 4.0

Deferred Stenting as an Alternative Strategy for Management of ST-Elevation Myocardial Infarction with Significant Thrombus Burden

M. Nadeem Attar, Ibrahim Bader, Michael F. Dorsch, Ben D. Tyrrell, Raymond Leung, Neil Brass, William Hui, Po Kee Cheung

Journal of Advances in Medicine and Medical Research · pp. 1–6 · Published 6 Sep 2015

10.9734/BJMMR/2015/20267

Abstract

Objectives: We evaluate a deferred stenting strategy following intense antithrombotic and antiplatelet therapy as an alternative to primary percutaneous coronary intervention with immediate stenting in ST-Elevation myocardial infarction (STEMI) patients with large thrombus burden. Methods: We identified all consecutive patients where a deferred stenting strategy was chosen as initial management strategy. Baseline characteristics, clinical outcomes and complications were collected from local and provincial databases. Procedural characteristics were evaluated from detailed review of angiograms.   Results: Between June 2011 and March 2014, thirty eight patients were treated with a deferred stenting strategy. TIMI thrombus grade scale 4 or 5 on the initial angiogram was seen in 82% of cases. Immediate thrombectomy or balloon angioplasty was performed in 25 out of 38 patients to restore flow. Aggressive antithrombotic (86% heparin) and antiplatelet (100% Eptifibatide and 100% dual antiplatelet therapy) was administered. No emergency repeat catheterisation was required. Thirty six patients had a relook angiogram. No further coronary intervention was required in 12/36 (33%) of patients, 23/36 (64%) patients received at least one stent and one patient was sent for coronary bypass surgery. No major bleeding occurred. One patient treated with deferred stenting died at 2 months from stent thrombosis. No other major adverse cardiovascular events occurred.   Discussion: In our experience deferred stenting is safe and has the potential to reduce no reflow and thereby reduce infarct size.

Deferred stenting primary percutaneous coronary intervention st-elevation myocardial infarction glycoprotein 2b/3a inhibitors.

Cited by 1

Article metrics

Real usage data collected on this platform.

10

Page views

0

PDF downloads

0

Outbound clicks

1

Citations

Views over time

Views by country

Approximate, from request IP at view time — not citizenship or institution. Countries with fewer than 5 views are grouped as "Other".

Traffic sources

Referring site, by host.

Views and downloads exclude known bots/crawlers. Citations combines this platform's own DOI-resolved index with each external source's own reported total — see Cited by above for individually listed citing works. Last refreshed 0 seconds ago.